Ozempic maker sheds $US475b and weight-loss crown after disastrous trial
--------------------------------------------------------------------
Source: The Age
Published: 2026-02-25 05:00 UTC+10:00
Section: Business / Companies
Factuality Score: 100
Opinion Category: Neutral
Topics: Sport, Economy & Finance, Financial Markets, Law & Courts, Drugs
--------------------------------------------------------------------
Snippet:
Novo Nordisk’s next-generation weight-loss drug CagriSema has been labelled obsolete before it even hits the market after the pharma giant’s trial results failed to match the performance of existing obesity drugs from rival Eli Lilly.
--------------------------------------------------------------------